KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) Operating Income (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Operating Income for 16 consecutive years, with $2.0 billion as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Operating Income rose 8.74% year-over-year to $2.0 billion, compared with a TTM value of $7.3 billion through Dec 2024, up 6.97%, and an annual FY2025 reading of $7.7 billion, up 5.57% over the prior year.
  • Operating Income was $2.0 billion for Q4 2024 at Thermo Fisher Scientific, up from $1.8 billion in the prior quarter.
  • Across five years, Operating Income topped out at $3.1 billion in Q4 2020 and bottomed at $906.0 million in Q1 2020.
  • Average Operating Income over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2022.
  • The sharpest move saw Operating Income soared 236.53% in 2021, then tumbled 44.59% in 2023.
  • Year by year, Operating Income stood at $3.1 billion in 2020, then fell by 17.36% to $2.5 billion in 2021, then fell by 26.67% to $1.9 billion in 2022, then decreased by 0.38% to $1.9 billion in 2023, then rose by 8.74% to $2.0 billion in 2024.
  • Business Quant data shows Operating Income for TMO at $2.0 billion in Q4 2024, $1.8 billion in Q3 2024, and $1.8 billion in Q2 2024.